Clin Osteol 2003; 8(1): 8-13

Recommended guidelines for diagnosis and treatment of postmenopausal osteoporosisArticles

Published: June 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Recommended guidelines for diagnosis and treatment of postmenopausal osteoporosis. Osteologický bulletin. 2003;8(1):8-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anonymous: Assessment of fracture risk and its application to screening for postme­ nopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. Vol. 843. Geneva: World Health Organisation, 1994.
    2. Black DM, Palermo L, Nevitt MC et al. Defining incident vertebral deformity: a pro­ spective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:90-101. Go to original source...
    3. Black DM, Thompson DE, Bauer DC et al (FIT Research Group). Fracture risk re­ duction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124. Go to original source...
    4. Brown JP, Josse RG, Canada TSACotOSo. 2002 clinical practice guidelines for the di­ agnosis and management of osteoporosis in Canada. CMAJ 2002;12,Suppl.10: 1-33.
    5. Cadarette SM, Jaglal SB, Murray TM et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001;286:57-63. Go to original source...
    6. Campbell AJ, Robertson MC, Gardner MM et al. Randomized controlled trial of a ge­ neral practice programme of home based exercise to prevent falls in elderly wo­ men. BMJ 1997;315:1065-1069. Go to original source...
    7. Chrischilles EA, Butler CD, Davis CS et al. A model of lifetime osteoporosis impact [published erratum appears in Arch Intern Med 1922 Mar;152(3):655]. Arch In­ tern Med 1991;151:2026-32. Go to original source...
    8. Close J, Ellis M, Hooper R et al. Prevention of falls in the elderly trial (PROFET): a randomized controlled trial. Lancet 1999;353:93-97. Go to original source...
    9. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for predic­ tion of hip fractures. The Study of Osteoporotic Fractures Research Group [see comments]. Lancet 1993;341:72-5. Go to original source...
    10. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-73. Go to original source...
    11. Dargent Molina P, Favier F, Grandjean H et al. Fall-related factors and risk ofhip frac­ ture: the EPIDOS prospective study. Lancet 1996;348:145-9. Go to original source...
    12. Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone tur­ nover in osteoporosis. Committee of Scientific Advisors of the International Os­ teoporosis Foundation. Osteoporosis Int 2000;11,Suppl.6:2-17. Go to original source...
    13. Faulkner KG, McClung MR. Quality control of DXA instruments in multicenter tri­ als. Osteoporosis Int 1995;5:218-27. Go to original source...
    14. Harris ST, Watts NB, Genant HK et al (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized con­ trolled trial. JAMA 1999;282:1344-1352. Go to original source...
    15. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical En­ docrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001;7:293-312.
    16. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foun­ dation. Osteoporosis Int 2000;11:192-202. Go to original source...
    17. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95. Go to original source...
    18. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synt­ hesis. J Bone Miner Res 2000;15:721-39. Go to original source...
    19. Liberman UA, Weiss SR, Broll J et al (Alendronate Phase III Osteoporosis Treatment Study Group). Effect of oral alendronate on bone mineral density and the inci­ dence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333: 1437-1443. Go to original source...
    20. Lindsay R, Cosman F, Lobo RA et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled cli­ nical trial. J Clin Endocrinol Metab 1999;84:3076-3081. Go to original source...
    21. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3. Go to original source...
    22. Lowe CE, Depew WT, Vanner SJ et al. Upper gastrointestinal toxicity of alendrona­ te. Am J Gastroenterol 2000;95:634-640. Go to original source...
    23. MacKelvie KJ, McKay HA, Petit MA et al. Bone mineral responses to a 7 month ran­ domized controlled, school-based jumping intervention in 121 prepubertal boys: associations with ethnicity and body mass index. J Bone Miner Res 2002;17: 834-844. Go to original source...
    24. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mine­ ral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9. Go to original source...
    25. McClung MR, Geusens P, Miller PD et al. Effect ofrisedronate on the risk ofhip frac­ ture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40. Go to original source...
    26. Melton LJ, Atkinson EJ, O'Connor MK et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23. Go to original source...
    27. Melton LJ, Atkinson EJ, Cooper C et al. Vertebral fractures predict subsequent frac­ tures. Osteoporosis Int 1999;10:214-21. Go to original source...
    28. NIH Consensus Development J^nel on Osteoporosis Prevention D, Therapy. Osteo­ porosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95. Go to original source...
    29. Petit MA, McKay HA, MacKelvie KJ et al. A randomized school-based jumping in­ tervention confers site and maturity-specific benefits on bone structural properti­ es in girls: a hip structural analysis study. J Bone Miner Res 2002;17:363-372. Go to original source...
    30. Pols HA, Felsenberg D, Hanley DA et al (Fosamax International Trial Study Group). Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999;9:461-468. Go to original source...
    31. Ravn P, Overgaard K, Huang C et al. Comparison of bone densitometry of the pha­ langes, distal forearm and axial skeleton in early postmenopausal women partici­ pating in the EPIC Study. Osteoporos Int 1996;6:308-13. Go to original source...
    32. Ravn P, Weiss SR, Rodriguez-Portales JA et al (Alendronate Osteoporosis Prevention Study Group). Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000; 85:1492-1497. Go to original source...
    33. Reginster J, Minne HW, Sorensen OH et al (Vertebral Efficacy with Risedronate The­ rapy [VERT] Study Group). Randomized trial of the effects of risedronate on ver­ tebral fractures in women with established postmenopausal osteoporosis. Osteo­ porosis Int 2000;11:83-91. Go to original source...
    34. Riggs BL, Melton LJ. Bone turnover matters: the raloxifene treatment paradox of dra­ matic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-4. Go to original source...
    35. Rosenthall L, Caminis J, Tenehouse A Calcaneal ultrasonometry: response to treat­ ment in comparison with dual x-ray absorptiometry measurements of the lumbar spine and femur. Calcif Tissue Int 1999;64:200-4. Go to original source...
    36. Ross P, Huang C, Davis J et al. Predicting vertebral deformity using bone densito­ metry at various skeletal sites and calcaneus ultrasound. Bone 1995;16:325-32. Go to original source...
    37. Schnitzer T, Bone HG, Crepaldi G et al (Alendronate Once-Weekly Study Group). Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging 2000;12:1-12. Go to original source...
    38. Stepan J, Havelka S, Kamberská Z, Bernátová M. Epidemiologie der Osteoporose in der Tschechischen Republik. J Mineralstoffwechsel 2002;9:7-13.
    39. Stock JL, Bell NH, Chesnut CH III et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after dis­ continuation of alendronate in postmenopausal women. Am J Med 1997;103: 291-297. Go to original source...
    40. Tonino RP, Meunier PJ, Emkey R et al (Phase III Osteoporosis Treatment Study Group). Skeletal benefits of alendronate: 7-year treatment of postmenopausal os­ teoporotic women. J Clin Endocrinol Metab 2000;85:3109-3115. Go to original source...
    41. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996; 11:293-7. Go to original source...
    42. Van Haastregt JC, Diederiks JP, van Rossum E et al. Effects of a programme of mul­ tifactorial home visits on falls and mobility impairments in elderly people at risk: a randomized controlled trial. BMJ 2000;321:994-998. Go to original source...
    43. Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000. Go to original source...
    44. Wolff I, Van Croonenborg JJ, Kemper HCG et al. The effect of exercise training pro­ grams on bone mass: A meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporosis Int 1999;9:1-12. Go to original source...
    45. Woodhouse A, Black DM. BMD at various sites for the prediction of hip fractures: a meta analysis. J Bone Miner Res 2000;15,Suppl.1:145

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.